Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ebert

Showing results (311-320 of 483) with videos related to

Pageof 49
Sort By:
The Journal of Biological Chemistry|January 19, 2020
Activating transcription factor 4 (ATF4) promotes skeletal muscle atrophy by forming a heterodimer with the transcriptional regulator C/EBPβScott M Ebert, Steven A Bullard, Nathan Basisty, et al.
Frontiers in Immunology|June 30, 2023
Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapyChad Pickering, Paul Aiyetan, Gege Xu, et al.
ESMO Open|September 11, 2024
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)R-D Hofheinz, F Herrle, T Dechow, et al.
ESMO Open|February 22, 2025
Corrigendum to "mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)": [ESMO Open 9 (2024) 103703]R-D Hofheinz, F Herrle, T Dechow, et al.
Cancer Research|January 30, 2009
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine designLisa M Ebert, Yu Chih Liu, Craig S Clements, et al.
Geroscience|April 4, 2023
The transcription regulator ATF4 is a mediator of skeletal muscle agingMatthew J Miller, George R Marcotte, Nathan Basisty, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 31, 2019
ULK2 is essential for degradation of ubiquitinated protein aggregates and homeostasis in skeletal muscleJordan D Fuqua, Caleb P Mere, Ana Kronemberger, et al.
Oncotarget|June 25, 2016
Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcomeLih Yin Tan, Chris Mintoff, M Zahied Johan, et al.
Science Advances|October 25, 2023
Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastomaBrett W Stringer, Manam Inushi De Silva, Zarina Greenberg, et al.
The Journal of Nutrition|December 27, 2021
Biology of Activating Transcription Factor 4 (ATF4) and Its Role in Skeletal Muscle AtrophyScott M Ebert, Blake B Rasmussen, Andrew R Judge, et al.
Pageof 49

Showing results (311-320 of 483) with videos related to

Sort By:
Pageof 49
The Journal of Biological Chemistry|January 19, 2020
Activating transcription factor 4 (ATF4) promotes skeletal muscle atrophy by forming a heterodimer with the transcriptional regulator C/EBPβScott M Ebert, Steven A Bullard, Nathan Basisty, et al.
Frontiers in Immunology|June 30, 2023
Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapyChad Pickering, Paul Aiyetan, Gege Xu, et al.
ESMO Open|September 11, 2024
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)R-D Hofheinz, F Herrle, T Dechow, et al.
ESMO Open|February 22, 2025
Corrigendum to "mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)": [ESMO Open 9 (2024) 103703]R-D Hofheinz, F Herrle, T Dechow, et al.
Cancer Research|January 30, 2009
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine designLisa M Ebert, Yu Chih Liu, Craig S Clements, et al.
Geroscience|April 4, 2023
The transcription regulator ATF4 is a mediator of skeletal muscle agingMatthew J Miller, George R Marcotte, Nathan Basisty, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 31, 2019
ULK2 is essential for degradation of ubiquitinated protein aggregates and homeostasis in skeletal muscleJordan D Fuqua, Caleb P Mere, Ana Kronemberger, et al.
Oncotarget|June 25, 2016
Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcomeLih Yin Tan, Chris Mintoff, M Zahied Johan, et al.
Science Advances|October 25, 2023
Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastomaBrett W Stringer, Manam Inushi De Silva, Zarina Greenberg, et al.
The Journal of Nutrition|December 27, 2021
Biology of Activating Transcription Factor 4 (ATF4) and Its Role in Skeletal Muscle AtrophyScott M Ebert, Blake B Rasmussen, Andrew R Judge, et al.
Pageof 49